FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compound of general formula
possessing CETP-inhibiting activity. In formula (I) R1 represents hydrogen atom, C1-C6 alkyl group, hydroxy(C1-C6alkyl) group, (C1-C6alkoxy)-(C1-C6alkyl) group, (C1-C6alkyl)amino-(C1-C6alkyl) group, [N-(C1-C6alkyl)-N-hydroxy(C1-C6 alkyl)amino]-(C1-C6alkyl) group, [N-(C1-C6alkyl)-N-(C1-C6 alkyl)sulphonylamino]-(C1-C6alkyl) group, carboxy(C1-C6alkyl) group, halogen (C1-C6alkyl) group, C2-C6alkenyl group, C3-C8cycloalkyl group, C3-C8cycloalkenyl group, hydroxyl group, C1-C6alkoxy group, hydroxy(C1-C6alkoxy) group, (C1-C6alkyl)sulphonyl-(C1-C6alkoxy) group, carboxy(C1-C6 alkoxy) group, halogen(C1-C6alkoxy) group, C1-C6 alkylthio group, C1-C6alkylsulphonyl group, N-(C1-C6alkyl)-N-hydroxy(C1-C6alkyl)aminogroup, carboxy group, (C1-C6 alkoxy)carbonyl group, (C1-C6 alkylamino)carbonyl group, di(C1-C6 alkyl)aminocarbonyl group, cyanogroup, halogen group, substituted phenyl group, in which substituent(substituents) represent 1-4 groups, independently selected from substituting group α, substituted with 5-membered aromatic heterocyclic group, containing 3 heteroatoms, selected from N and O, in which substituent (substituents) represent 1-4 groups, independently selected from substituting group α, 6-membered saturated heterocyclic group, containing 1-2 heteroatoms, selected from N, S and O, substituted 5- or 6-membered saturated heterocyclyl group, containing 1-2 heteroatoms, selected from N and S, in which substituent (substituents) represent 1-4 groups, independently selected from substituting group α, substituted 5- or 6-membered saturated heterocyclyloxy group, containing 1 heteroatom, selected from N, in which substituent (substituents) represent 1-4 groups, independently selected from substituting group α, 6-membered saturated heterocyclylcarbonyl group, containing 2 heteroatoms, selected from N and O, and substituting group α represents group, consisting of C1-C6 alkyl group, hydroxyl group, carboxy group, (C1-C6 alkoxy)carbonyl group and oxogroup.
EFFECT: invention relates to pharmaceutical composition, containing said compound, to medication for increasing concentration of cholesterol of high-density lipoproteins or for reduction of concentration of cholesterol of low-density lipoproteins and to method of treating or preventing disease, mediated by CETP activity.
53 cl, 2 tbl, 58 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | 2019 |
|
RU2812726C2 |
| NEW TETRAHYDROPYRIMIDINE CONNECTION OR ITS SALT | 2015 |
|
RU2636310C1 |
| PYRIDINONE PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | 2007 |
|
RU2472782C2 |
| BICYCLIC DIHYDROPYRIMIDINECARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 2017 |
|
RU2778478C2 |
| CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF FOR INHIBITING NOREPINEPHRINE, DOPAMINE AND SEROTONIN REUPTAKE | 2005 |
|
RU2388751C2 |
| HETEROCYCLIC COMPOUND | 2018 |
|
RU2768473C2 |
| MODULATORS OF ATP-BINDING TRANSPORTERS | 2010 |
|
RU2552353C2 |
| PIPERIDINE DERIVATIVES | 2011 |
|
RU2554353C2 |
